Sunitinib-Induced Adrenal Crisis in a Patient with Pre-Existing Immunotherapy-Related Hypopituitarism
Sign Up to like & getrecommendations! Published in 2022 at "Case Reports in Oncology"
DOI: 10.1159/000521206
Abstract: Sunitinib is a tyrosine kinase inhibitor that is frequently used in the treatment of metastatic renal cell carcinoma (mRCC). As a multikinase inhibitor, numerous off-target side effects of this medication are widely recognized. More recently,… read more here.
Keywords: sunitinib induced; hypopituitarism; related hypopituitarism; induced adrenal ... See more keywords